Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Oct;185(4):756-763.
doi: 10.1111/bjd.19813. Epub 2021 Mar 18.

Relationship between type 2 diabetes mellitus and markers of cutaneous melanoma aggressiveness: an observational multicentric study in 443 patients with melanoma

E Nagore  1   2 , M A Martinez-Garcia  3   4 , J D Gomez-Olivas  3 , E Manrique-Silva  1   2 , A Martorell  5 , J Bañuls  6 , C Carrera  7 , P Ortiz  8 , J Gardeazabal  9 , A Boada  10 , E de Eusebio  11 , E Chiner  12 , C Gonzalez  13 , A Pérez-Gil  14 , D Cullen  15 , M Formigón  16 , B de Unamuno  17 , C Navarro-Soriano  3 , A Muriel  18 , D Gozal  19
Affiliations
Observational Study

Relationship between type 2 diabetes mellitus and markers of cutaneous melanoma aggressiveness: an observational multicentric study in 443 patients with melanoma

E Nagore et al. Br J Dermatol. 2021 Oct.

Abstract

Background: Some studies have suggested a relationship between type 2 diabetes mellitus (T2DM) and increased incidence of melanoma. Efforts are under way to identify preventable and treatable factors associated with greater melanoma aggressiveness, but no studies to date have examined the relationship between T2DM and the aggressiveness of cutaneous melanoma at diagnosis.

Objectives: To explore potential associations between T2DM, glycaemic control and metformin treatment and the aggressiveness of cutaneous melanoma.

Methods: We conducted a cross-sectional multicentric study in 443 patients diagnosed with cutaneous melanoma. At diagnosis, all patients completed a standardized protocol, and a fasting blood sample was extracted to analyse their glucose levels, glycated haemoglobin concentration and markers of systemic inflammation. Melanoma characteristics and aggressiveness factors [Breslow thickness, ulceration, tumour mitotic rate (TMR), sentinel lymph node (SLN) involvement and tumour stage] were also recorded.

Results: The mean (SD) age of the patients was 55·98 (15·3) years and 50·6% were male. The median Breslow thickness was 0·85 mm. In total, 48 (10·8%) patients were diagnosed with T2DM and this finding was associated with a Breslow thickness > 2 mm [odds ratio (OR) 2·6, 95% confidence interval (CI) 1·4-4·9; P = 0·004)] and > 4 mm (OR 3·6, 95% CI 1·7-7·9; P = 0·001), TMR > 5 per mm2 (OR 4·5, 95% CI 1·4-13·7; P = 0·009), SLN involvement (OR 2·3, 95% CI 1-5·7; P = 0·038) and tumour stages III-IV (vs. I-II) (OR 3·4, 95% CI 1·6-7·4; P = 0·002), after adjusting for age, sex, obesity, alcohol intake and smoking habits. No significant associations emerged between glycated haemoglobin levels, metformin treatment and melanoma aggressiveness.

Conclusions: T2DM, rather than glycaemic control and metformin treatment, is associated with increased cutaneous melanoma aggressiveness at diagnosis.

PubMed Disclaimer

Comment in

References

    1. Gracia-Cazaña T, González S, Parrado C et al. Influence of the exposome on skin cancer. Actas Dermosifiliogr 2020; 111:460-70.
    1. Lennon H, Badrick E, Sperrin M, Renehan AG. Body-mass index and metastasic melanoma outcomes. Lancet Oncol 2018; 19:e225.
    1. Sergentaris TN, Antoniadis AG, Gogas HJ et al. Obesity and risk of malignant melanoma. a meta-analysis of cohort and case-control studies. Eur J Cancer 2013; 4:642-57.
    1. Gandini S, Masala G, Palli D et al. Alcohol, alcoholic beverages, and melanoma risk: a systematic literature review and dose-response meta-analysis. Eur J Nutr 2018; 57:2323-32.
    1. Nagore E, Hueso L, Botella-Estrada R et al. Smoking, sun exposure, number of nevi and previous neoplasias are risk factors for melanoma in older patients (60 years and over). J Eur Acad Dermatol Venereol 2010; 24:50-7.

Publication types